Ingrid Pabinger
#135,399
Most Influential Person Now
Researcher
Ingrid Pabinger's AcademicInfluence.com Rankings
Ingrid Pabingerbiology Degrees
Biology
#9237
World Rank
#12419
Historical Rank
Biotechnology
#124
World Rank
#126
Historical Rank
Molecular Biology
#1239
World Rank
#1266
Historical Rank
Download Badge
Biology
Ingrid Pabinger's Degrees
- PhD Biomedical Sciences Medical University of Vienna
- Masters Biotechnology University of Vienna
- Bachelors Biotechnology University of Vienna
Why Is Ingrid Pabinger Influential?
(Suggest an Edit or Addition)Ingrid Pabinger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (796)
- Increased fetal loss in women with heritable thrombophilia (1996) (670)
- Prediction of venous thromboembolism in cancer patients. (2010) (661)
- International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer (2013) (636)
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. (2014) (394)
- High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). (2007) (385)
- Romiplostim or standard of care in patients with immune thrombocytopenia. (2010) (365)
- A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms (2009) (364)
- D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. (2009) (363)
- 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2019) (359)
- Wilson's disease in patients presenting with liver disease: a diagnostic challenge. (1997) (351)
- Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial (2008) (313)
- International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. (2016) (311)
- Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis (2020) (294)
- High D-dimer levels are associated with poor prognosis in cancer patients (2012) (279)
- International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer (2012) (271)
- Cancer-associated venous thromboembolism: Burden, mechanisms, and management (2016) (270)
- The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study (2009) (268)
- Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*) (1995) (257)
- A single genetic origin for a common Caucasian risk factor for venous thrombosis. (1997) (250)
- Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism (1998) (248)
- Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients (2012) (239)
- Risk of pregnancy‐associated recurrent venous thromboembolism in women with a history of venous thrombosis (2005) (217)
- High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) (2010) (213)
- Biomarkers for prediction of venous thromboembolism in cancer. (2013) (212)
- Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. (2011) (205)
- Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) (2005) (197)
- Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. (2002) (196)
- Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study (2015) (194)
- Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. (2015) (194)
- Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. (1996) (194)
- Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. (2013) (185)
- A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. (2018) (179)
- Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer (2013) (176)
- Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening (1992) (172)
- Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. (1998) (171)
- Protein S Deficiency: A Database of Mutations – Summary of the First Update (2000) (162)
- Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients (2018) (160)
- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. (2016) (149)
- Venous Thromboembolism , Thrombophilia , Antithrombotic Therapy , and Pregnancy (2008) (148)
- Biomarkers and Venous Thromboembolism (2009) (145)
- Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?* (2003) (142)
- Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. (2017) (140)
- High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients: The Cancer and Thrombosis Study (2009) (136)
- Clinical significance of lupus anticoagulants in children. (1999) (135)
- Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. (1997) (132)
- Factor V Enhances the Cofactor Function of Protein S in the APC-Mediated Inactivation of Factor VIII: Influence of the Factor VR506Q Mutation (1996) (128)
- High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. (2007) (124)
- Venous thromboembolism and survival in patients with high-grade glioma. (2007) (124)
- Venous thromboembolism--a manifestation of the metabolic syndrome. (2007) (120)
- Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig‐Therasorb) (2001) (117)
- Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis (2017) (111)
- The postoperative splenic/portal vein thrombosis after splenectomy and its prevention – an unresolved issue (2008) (107)
- Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. (2012) (106)
- Probability of Recurrence of Thrombosis in Patients with and without Factor V Leiden (1996) (104)
- Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia (2005) (104)
- Diagnostic high-throughput sequencing of 2,390 patients with bleeding, thrombotic and platelet disorders (2018) (103)
- Thrombin generation in morbid obesity: significant reduction after weight loss (2010) (99)
- Prevention of Arterial and Pulmonary Embolism by Oral Anticoagulants in Patients with Dilated Cardiomyopathy (1985) (95)
- The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant (2005) (93)
- Familial thrombophilia and lifetime risk of venous thrombosis (2004) (93)
- The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. (2006) (93)
- Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) (2021) (91)
- Protein S Deficiency: A Database of Mutations (1997) (90)
- The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH (2019) (90)
- Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII (2017) (89)
- Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers (2007) (88)
- Hereditary thrombophilia and fetal loss: a prospective follow‐up study (2004) (87)
- Platelets in cancer and thrombosis (2014) (87)
- Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials (2013) (87)
- Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia (2002) (86)
- Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. (2020) (86)
- Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates (1987) (85)
- Edoxaban for treatment of venous thromboembolism in patients with cancer (2015) (85)
- Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer (2018) (82)
- Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study. (1997) (80)
- Circulating procoagulant microparticles in cancer patients (2011) (79)
- Thrombophilia and pregnancy outcomes (2005) (78)
- Rituximab for the treatment of acquired antibodies to factor VIII. (2007) (77)
- The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. (2003) (77)
- Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality (2014) (73)
- Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A (2016) (72)
- Preeclampsia and Fetal Loss in Women With a History of Venous Thromboembolism (2001) (72)
- Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. (2016) (71)
- Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI (2018) (71)
- Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. (2000) (70)
- Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). (2014) (70)
- The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera (2009) (70)
- ORAL CONTRACEPTIVES ENHANCE THE RISK OF CLINICAL MANIFESTATION OF VENOUS THROMBOSIS AT A YOUNG AGE IN FEMALES HOMOZYGOUS FOR FACTOR V LEIDEN (1996) (70)
- Peripheral blood microvesicles secretion is influenced by storage time, temperature, and anticoagulants (2016) (69)
- Elimination of Acquired Factor VIII Antibodies by Extracorporal Antibody-based Immunoadsorption (Ig-Therasorb®) (1995) (68)
- Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants (2019) (67)
- Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. (2014) (66)
- Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients (2008) (65)
- Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality (2015) (65)
- Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions (2002) (65)
- Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study (2013) (65)
- Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials (2012) (64)
- Microparticle‐associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features (2013) (64)
- Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) (2015) (63)
- Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels (2014) (62)
- Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study (1996) (62)
- Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer (2019) (61)
- FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia (1996) (60)
- Pregnancy-associated thrombosis (2003) (60)
- Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). (2015) (60)
- Hypercoagulabilty, venous thromboembolism, and death in patients with cancer (2016) (59)
- Anti-β2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant (2006) (59)
- Thrombosis during pregnancy: risk factors, diagnosis and treatment (2002) (59)
- Low‐density lipoprotein receptor‐related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism (2007) (58)
- Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH (2014) (58)
- Pregnancy complications and obstetric care in women with inherited bleeding disorders (2013) (58)
- Circulating procoagulant microparticles in patients with venous thromboembolism. (2009) (57)
- Protein S deficiency type I: identification of point mutations in 9 of 10 families. (1995) (56)
- Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma (2012) (56)
- Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate (2010) (56)
- Endothelial dysfunction in patients with polycythaemia vera (2001) (56)
- Homozygous Antithrombin Deficiency: Report of Two New Cases (99 Leu to Phe) Associated with Arterial and Venous Thrombosis (1994) (55)
- Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. (2013) (55)
- Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
- Thrombosis risk and survival in cancer patients with elevated C‐reactive protein (2011) (53)
- Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI) (2017) (53)
- Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). (2018) (53)
- Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. (2001) (51)
- Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. (2016) (51)
- Laboratory issues in bleeding disorders (2006) (51)
- Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A (2015) (51)
- Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. (2014) (50)
- Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates (2017) (50)
- The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs (2008) (49)
- Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. (2011) (49)
- Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment (2016) (49)
- Spontaneous remission of acute myeloid leukemia after infection and blood transfusion associated with hypergammaglobulinaemia (1996) (49)
- Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials (2020) (49)
- Homocysteine levels in polycythaemia vera and essential thrombocythaemia (1999) (47)
- Comparative pharmacokinetics of rVIII‐SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A (2016) (47)
- European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. (2017) (46)
- Hereditary Protein C-Deficiency: Laboratory Values in Transmitters and Guidelines for the Diagnostic Procedure Report on a Study of the SSC Subcommittee on Protein C and Protein S (1992) (46)
- Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia (2007) (46)
- Platelet kinetics and scintigraphic imaging in thrombocytopenic malaria patients (2004) (42)
- Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism (2005) (42)
- Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies (2019) (42)
- Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. (2016) (42)
- Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism (2018) (41)
- Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism: Results of a Patient-Level Meta-Analysis (2014) (40)
- The Prevalence of Hereditary Antithrombin-III Deficiency in Patients with a History of Venous Thromboembolism (1985) (40)
- Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A (2004) (40)
- Tests predictive of thrombosis in cancer. (2010) (40)
- Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia (2016) (39)
- Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria (2007) (39)
- Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. (2012) (38)
- Association of platelet activation markers with cancer-associated venous thromboembolism (2016) (38)
- Cancer-associated venous thromboembolism (2022) (38)
- Clinical significance of circulating microparticles for venous thrombo - embolism in cancer patients (2012) (37)
- Fertility, pregnancies and offspring complications after bone marrow transplantation. (1991) (37)
- Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women (2010) (36)
- Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study (2020) (36)
- Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art (2015) (36)
- Venous Thromboembolism - A Manifestation of the Metabolic Syndrome?. (2006) (36)
- Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. (2021) (36)
- Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis (2016) (36)
- Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib (2016) (35)
- The role of podoplanin in cancer-associated thrombosis. (2018) (35)
- Transient lupus anticoagulant associated with hypoprothrombinemia and Factor XII deficiency following adenovirus infection (1993) (35)
- High proportion of patients with bleeding of unknown cause in persons with a mild‐to‐moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB) (2018) (35)
- Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report (2019) (35)
- Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS) (2015) (34)
- 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 (2022) (34)
- Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban (2015) (34)
- Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety (2016) (33)
- Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients (2014) (33)
- Anti-factor xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. (2009) (33)
- Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome (1997) (33)
- Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. (2005) (33)
- Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. (1998) (33)
- P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism (2008) (33)
- Atrial fibrillation in patients with haemophilia: a cross‐sectional evaluation in Europe (2014) (33)
- Transient Lupus Anticoagulants in Children: Stepwise Disappearance of Diagnostic Features (2000) (32)
- Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer (2018) (32)
- Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate (2010) (32)
- No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene. (1999) (32)
- Inflammation in patients with lupus anticoagulant and implications for thrombosis. (2005) (32)
- Prothrombin Fragment F1+2 Is not Predictive for Recurrent Venous Thromboembolism (1997) (31)
- Interleukin-6 and interleukin-6 promoter polymorphism (−174) G>C in patients with spontaneous venous thromboembolism (2006) (31)
- Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. (1990) (31)
- Alterations of blood coagulation in controlled human malaria infection (2016) (30)
- The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study (2019) (30)
- FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. (2016) (29)
- Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006 (2009) (29)
- Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia (2003) (29)
- Lipoprotein (a) in patients with spontaneous venous thromboembolism. (2007) (29)
- Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia (2013) (28)
- Evaluation of bedside prothrombin time and activated partial thromboplastin time measurement by coagulation analyzer CoaguCheck Plus in various clinical settings. (1997) (28)
- Risk of recurrence after a first venous thromboembolic event in young women (2007) (28)
- Safety, efficacy and pharmacokinetics of rVIII‐SingleChain in children with severe hemophilia A: results of a multicenter clinical trial (2017) (28)
- Flamethrowers: blood cells and cancer thrombosis risk. (2014) (27)
- The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154 (2007) (27)
- Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. (2009) (27)
- Agonist‐inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia (2007) (27)
- Lupus anticoagulants: strong association with the major histocompatibility complex class II and platelet antibodies (1997) (27)
- Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients (2012) (26)
- Mortality and inherited thrombophilia: results from the European Prospective Cohort on Thrombophilia (2012) (26)
- (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations (1994) (26)
- How I treat cancer-associated thrombosis (2020) (26)
- Surgical treatment of the haemophilic pseudotumour: A single centre experience (2012) (26)
- Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. (2006) (25)
- Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. (2014) (25)
- Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. (2014) (25)
- Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study (2020) (24)
- Risk of venous thromboembolism and primary prophylaxis in cancer (2012) (24)
- Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. (2014) (24)
- Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease (2012) (23)
- Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin (2004) (23)
- Spectrum of causative mutations in patients with haemophilia A in Austria (2010) (23)
- Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer (2019) (23)
- Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. (1996) (22)
- Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism (2013) (22)
- Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation (2018) (21)
- Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery (2016) (21)
- Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) (21)
- Anticoagulation during pregnancy. (2003) (21)
- Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis (1998) (21)
- Histone citrullination as a novel biomarker and target to inhibit progression of abdominal aortic aneurysms. (2021) (20)
- BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results (2019) (20)
- Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. (2014) (20)
- Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study (2015) (20)
- Acquired immune-mediated thrombophilia in lymphoproliferative disorders (2011) (20)
- Anti-cardiolipin antibodies and overall survival in a large cohort: preliminary report. (2006) (20)
- Resistance to activated protein C (APC): mutation at ARG506 of coagulation factor V and vascular access thrombosis in haemodialysis patients (1996) (19)
- Pulmonary embolism during the COVID‐19 pandemic: Decline in diagnostic procedures and incidence at a university hospital (2020) (19)
- ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo (2021) (19)
- Risk of recurrence after a first venous thromboembolic event in young women. (2007) (19)
- The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism (2012) (19)
- The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism (2007) (19)
- Long-term survival of patients with a history of venous thromboembolism (2010) (18)
- Haptoglobin phenotype 2-2 as a potentially new risk factor for spontaneous venous thromboembolism. (2005) (18)
- 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. (1990) (18)
- Clinical significance of anti-protein Z antibodies in patients with lupus anticoagulant. (2008) (18)
- Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide (2006) (18)
- Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia (2006) (18)
- Platelet activation and function during eltrombopag treatment in immune thrombocytopenia (2011) (18)
- Neutrophil-Mediated Proteolysis of Thrombospondin-1 Promotes Platelet Adhesion and String Formation (2018) (18)
- Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications (2017) (18)
- Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. (2021) (18)
- Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. (2020) (18)
- Diagnosis of Protein C Deficiency in Patients on Oral Anticoagulant Treatment: Comparison of Three Different Functional Protein C Assays (1990) (17)
- Deficiency of fibrinogen and factor VII following treatment of severe aplastic anaemia with anti-thymocyte globulin and high-dose methylprednisolone. (2009) (17)
- Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. (2020) (17)
- Combinatorial peptides directed to inhibitory antibodies against human blood clotting factor VIII (2005) (17)
- Decrease in microvesicle-associated tissue factor activity in morbidly obese patients after bariatric surgery (2016) (17)
- Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer (2020) (17)
- How I Treat Patients with Hereditary Antithrombin Deficiency. (2019) (17)
- Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry (2016) (17)
- Recurrent, Isolated Factor X Deficiency in Myeloma: Repeated Normalization of Factor X Levels after Cytostatic Chemotherapy Followed by Late Treatment Failure Associated with the Development of Systemic Amyloidosis (1992) (17)
- Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis. (2020) (16)
- Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients (2015) (16)
- HLA class-I and -II antigens in chronic idiopathic autoimmune thrombocytopenia (1994) (16)
- C-reactive protein 3' UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. (2006) (16)
- Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. (2014) (16)
- Management of atrial fibrillation in people with haemophilia – a consensus view by the ADVANCE Working Group (2014) (16)
- The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients (2020) (16)
- Thrombophilia and its impact on pregnancy. (2009) (16)
- Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A (2009) (16)
- Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause (2019) (16)
- Procoagulant extracellular vesicles in amniotic fluid (2017) (16)
- Thrombin generation in patients with a bleeding tendency of unknown origin (2011) (16)
- In utero exposure to Azathioprine in autoimmune disease. Where do we stand? (2020) (15)
- Postpartum factor VIII inhibitors. Report of two cases with special reference to the efficacy of various treatments. (1993) (15)
- Clinical relevance of protein C (1986) (15)
- Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. (2021) (15)
- The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. (2007) (15)
- Successful outcome in a pregnant woman with homozygous antithrombin deficiency (2007) (15)
- Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles (2020) (15)
- Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. (2020) (14)
- Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause (2016) (14)
- Cerebral sinus thrombosis in a patient with hereditary protein S deficiency: Case report and review of the literature (1992) (14)
- Venöse Thrombembolien bei Tumorpatienten (2011) (14)
- Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance. (1996) (14)
- Traveller's thrombosis 2001. (2002) (14)
- Antithrombins Southport (Leu 99 to Val) and Vienna (Cln 118 to Pro): two novel antithrombin variants with abnormal heparin binding (1995) (13)
- Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause. (2020) (13)
- Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis (2020) (13)
- [Problems of long-term therapy with anticoagulants]. (1992) (13)
- A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability (2016) (13)
- VTE risk assessment in cancer (2016) (13)
- Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation (2021) (13)
- International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis (2016) (13)
- Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts (2020) (12)
- Late spontaneous remissions in severe adult autoimmune thrombocytopenia (2007) (12)
- Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study (2021) (12)
- High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. (2019) (12)
- Is the determination of anti‐beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome? (2003) (12)
- The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency. (2020) (12)
- Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting (2020) (12)
- Immune-Mediated Disorders Causing Bleeding or Thrombosis in Lymphoproliferative Diseases (2014) (12)
- Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH) (2017) (12)
- Pain management in hemophilia: expert recommendations (2021) (12)
- Platelets and hemophilia: A review of the literature. (2017) (12)
- Prevention of venous thromboembolism in ambulatory patients with cancer (2020) (12)
- An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal. (2015) (12)
- Austrian Hemophilia Registry: design, development and set of variables (2009) (12)
- Lupus anticoagulant and clinical correlates (1992) (11)
- PO-63 - Exhausted platelets in cancer patients with high risk of venous thromboembolism and poor prognosis. (2016) (11)
- Prognosis of patients with a second relapse of acute myeloid leukemia (2000) (11)
- Thrombophilia and pregnancy complications (2006) (11)
- [Treatment of haemophilia in Austria]. (2015) (11)
- Postoperative paraneoplastic factor VIII auto‐antibodies in patients with solid tumours (2011) (11)
- Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review (2021) (11)
- The FcγRIIa polymorphism R/H131, autoantibodies against the platelet receptors GPIbα and FcγRIIa and a risk for thromboembolism in lupus anticoagulant patients (2005) (11)
- Treatment and secondary prevention of venous thromboembolism in cancer patients (2012) (11)
- (8th Edition) Evidence-Based Clinical Practice Guidelines American College of Chest Physicians Antithrombotic Therapy, and Pregnancy: Venous Thromboembolism, Thrombophilia, (2008) (11)
- Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma (2019) (11)
- Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability (2021) (10)
- Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low-molecular-weight heparin (LMWH) during pregnancy (2006) (10)
- A frequent mutation in the protein S gene results in cryptic splicing (1997) (10)
- Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts (2013) (10)
- Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI). (2017) (10)
- A hitherto unknown splice site defect in the protein S gene (PROS1): the mutation results in allelic exclusion and causes type I and type III protein S deficiency (1997) (10)
- Trisomy 14 in refractory anemia with excess of blasts in transformation. (1987) (10)
- Erythrocytes as carriers for heparin (1986) (10)
- Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women (2010) (10)
- Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls (2021) (10)
- Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study (2020) (9)
- Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause (2015) (9)
- 3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross‐sectional comparative assessment of haemophilic arthropathy (2020) (9)
- Implementing Thrombosis Guidelines in Cancer Patients: A Review (2014) (9)
- Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN Study (2013) (9)
- Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population (2020) (9)
- Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017) (9)
- Drug-testing in patients with pulmonary hypertension of unknown cause. (1992) (9)
- Mortality in severe, non aggressively treated adult autoimmune thrombocytopenia. (2003) (9)
- A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS THROMBOEMBOLISM IN CANCER PATIENTS (2007) (9)
- Factor V Leiden as an independent risk factor for thrombosis in antithrombin deficiency type II: heparin binding site (1995) (9)
- Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis. (2020) (8)
- Identification of an ancient haemophilia A splice site mutation. (2012) (8)
- Response to antiplatelet therapy is independent of endogenous thrombin generation potential. (2013) (8)
- Impact of self‐administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider (2015) (8)
- Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A (2020) (8)
- Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals (2020) (8)
- Massive postoperative intramuscular bleeding in acquired von Willebrand's disease (2002) (8)
- Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer (2021) (8)
- Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation (2001) (8)
- OC-16 - Neutrophil extracellular traps and tissue factor-bearing microvesicles: a liaison dangereuse causing overt DIC in cancer patients? (2016) (8)
- Homozygous antithrombin deficiency type II causing neonatal thrombosis. (2017) (7)
- Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Polymorphism 663 C>T Affects Clotting Factor VIII Activity and Increases the Risk of Venous Thromboembolism. (2006) (7)
- ProCGlobal and endogenous thrombin potential during pregnancy. (2010) (7)
- [Immune thrombocytopenia -- onkopedic guidelines update: recommendations of a joint working group of the DGHO, ÖGHO, SGH + SSH and GPOH]. (2014) (7)
- Azidothymidine (AZT) in the Treatment of Symptomatic HIV-1-Infected Hemophiliacs (1990) (7)
- Lupus anticoagulant and thromboembolism: evaluation of fibrinogen, natural inhibitors and molecular markers of thrombosis (1996) (7)
- Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. (2021) (7)
- Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A (2019) (7)
- Specificities of Platelet Autoantibodies and Platelet Activation in Lupus Anticoagulant Patients: A Relation to their History of Thromboembolic Disease (2006) (7)
- Increased Citrullinated Histone H3 Levels in the Early Post-Resuscitative Period Are Associated with Poor Neurologic Function in Cardiac Arrest Survivors—A Prospective Observational Study (2019) (7)
- Outcome of osteotomies for the treatment of haemophilic arthropathy of the knee (2004) (7)
- Efficacy and Safety of Eltrombopag in Elderly Patients with Chronic Immune Thrombocytopenia: Analysis of Five Clinical Trials, (2011) (7)
- Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up. (2009) (7)
- Four year follow-up of the Duromedics Edwards bileaflet valve prostheses. (1990) (7)
- [Austrian Guidelines for Prophylaxis of Venous Thromboembolism]. (2007) (6)
- [Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]. (2012) (6)
- Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study (2017) (6)
- Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis (2018) (6)
- The Fc gammaRIIa polymorphism R/H131, autoantibodies against the platelet receptors GPIb alpha and Fc gammaRIIa and a risk for thromboembolism in lupus anticoagulant patients. (2005) (6)
- Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population‐based prospective cohort study (2021) (6)
- Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment (1999) (6)
- Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia (1991) (6)
- Influence of Imprinting of an X Chromosome and of the MethyleneTetrahydrofolate Reductase (MTHFR) 677C>T Polymorphism on FVIII Activity (2015) (5)
- Risk assessment models of cancer-associated thrombosis - Potentials and perspectives (2021) (5)
- Coumarin induced acral skin necrosis associated with hereditary protein C deficiency (1986) (5)
- Epidemiology and Treatment of Patients with Haemophilia in Austria—Update from the Austrian Haemophilia Registry (2018) (5)
- Association of elevated soluble P-selectin levels with fetal loss in women with a history of venous thromboembolism. (2012) (5)
- Limitations of a calibrated, quantitative APC‐R assay under routine conditions (2020) (5)
- Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma (2020) (5)
- The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year. (2010) (5)
- Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. (2020) (5)
- Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. (2021) (5)
- HLA HAPLOTYPE AND HIV INFECTION (1988) (5)
- Plasma levels of P-selectin are determined by platelet turn-over and the P-selectin Thr715Pro polymorphism. (2008) (5)
- Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE (2015) (5)
- High Levels of Soluble P-Selectin Are Associated with the Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant. (2006) (5)
- Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027 (2020) (4)
- Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism? (2017) (4)
- Peptides derived from a secretory yeast library restore factor VIII activity in the presence of an inhibitory antibody (2007) (4)
- Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study (2021) (4)
- ABO blood group type and risk of venous thromboembolism in patients with cancer (2022) (4)
- Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding (2018) (4)
- Austrian Haemophilia Registry (2009) (4)
- Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a (2016) (4)
- Longitudinal analysis of extracellular vesicle-associated tissue factor activity in cancer patients. (2020) (4)
- Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS) (2008) (4)
- Eltrombopag in chronic idiopathic thrombocytopenic purpura (2009) (4)
- [Oral anticoagulant therapy--renaissance of an old therapy?]. (1987) (4)
- The bleeding phenotype in people with nonsevere hemophilia (2022) (4)
- Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria (2021) (3)
- [Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]. (2014) (3)
- Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia (2015) (3)
- Acquired Deficiency of Fibrinogen (Fbg) and Factor VII (F VII) During and Following Immunosuppression for Severe Aplastic Anemia (SAA) with Antithymocyte Globulin (ATG) and High-Dose Methylprednisolone (MP) (1985) (3)
- Natural anticoagulants: A missing link in mild to moderate bleeding tendencies (2021) (3)
- Risk of venous thromboembolism and primary prophylaxis in cancer (2012) (3)
- Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites (2021) (3)
- Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome. (2008) (3)
- Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better? (1992) (3)
- Inhibition of tissue factor pathway inhibitor (TFPI) by ARC19499 improves clotting of hemophiliac blood (2010) (3)
- Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults? (2017) (3)
- Thrombotic Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant and Thrombosis Study (LATS) (2015) (2)
- Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery (2021) (2)
- [Update thrombophilia]. (2008) (2)
- Inhibitor development in two patients with mild haemophilia A – spontaneous disappearance and no recurrence of the inhibitor after re-challenge (2012) (2)
- Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study (2016) (2)
- [Home treatment in hemophilia]. (1987) (2)
- SP478PREVALENCE OF ATRIAL FIBRILLATION AND PRACTICE PATTERNS OF ANTITHROMBOTIC THERAPY IN A POPULATION-BASED COHORT STUDY OF HEMODIALYSIS PATIENTS: THE VIENNA INVESTIGATION OF ATRIAL FIBRILLATION AND THROMBOEMBOLISM IN HEMODIALYSIS PATIENTS (VIVALDI) (2016) (2)
- Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim (2014) (2)
- Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline†. (2023) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- Clinical-Pathological Conference Series from the Medical University of Graz Case No 155: 26-year-old woman in third trimester of pregnancy with epigastric pain and thrombocytopenia (2015) (2)
- Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study. (2014) (2)
- The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease (2022) (2)
- Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors (2021) (2)
- Effect of Eltrobopag on platelet response, bleeding and reduction in concomitant ITP medication in adults with chronic Immuno Thrombocytopenia (ITP) and baseline platelets = 15,000 /ml (2010) (2)
- Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study (2013) (2)
- PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients. (2016) (2)
- Interleukin‐4 receptor alpha signaling regulates monocyte homeostasis (2022) (2)
- Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study. (2014) (2)
- Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy. (2016) (2)
- CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV. (2015) (2)
- Platelet glycoprotein Ibα polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease (2007) (2)
- Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension (2018) (2)
- Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII (2022) (2)
- HEAT INACTIVATED HIGHLY PURIFIED FACTOR VIII CONCENTRATE IN THE TREATMENT OF HEMOPHILIACS (1987) (1)
- Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism (2021) (1)
- Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study (2017) (1)
- Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP) (2011) (1)
- Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study (2022) (1)
- Pierson syndrome (2020) (1)
- Decreased ADAMTS13 Activity Levels in Patients with a Bleeding Tendency of Unknown Origin (2011) (1)
- Erroneously low APC ratio in patients with lupus anticoagulant (1995) (1)
- Antithrombotic Therapy , and Pregnancy : Venous Thromboembolism , Thrombophilia (2008) (1)
- Fibrinolysis and bleeding of unknown cause (2021) (1)
- Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach. (2022) (1)
- Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill? (2002) (1)
- [Venous thromboembolism]. (2007) (1)
- Treatment of primary autoimmune thrombocytopenia (AITP) [1] (2012) (1)
- Metabolic syndrome and venous thrombosis: potential role of microparticles (2007) (1)
- A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. (2023) (1)
- Hemophilia 2001 — The Annual Survey of the Austrian Hemophilia Centers (2003) (1)
- Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year (2017) (1)
- New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia (2021) (1)
- Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS). (2012) (1)
- [Adult autoimmune thrombocytopenia: diagnosis and treatment]. (2006) (1)
- Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors (2022) (1)
- VTE risk assessment in cancer (2016) (1)
- Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study (2019) (1)
- Development and validation of a clinical prediction model for cancer-associated venous thromboembolism in two independent prospective cohorts (2020) (1)
- OC-13 A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts (2021) (1)
- Medical and Neuro-Oncology (2010) (1)
- Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies (2022) (1)
- von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. (2022) (1)
- The Role of Neutrophil Extracellular Traps in Cancer-Associated Arterial Thrombosis (2018) (1)
- Post-surgical hemorrhagic infarction of the adrenal gland as the first clinical manifestation of antiphospholipid syndrome after 43 years of antibody-positivity (2013) (1)
- The post-VTE functional status scale for assessment of functional limitations in patients with venous thromboembolism: Construct validity and responsiveness in a prospective cohort study. (2022) (1)
- Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study (2022) (1)
- Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group (2022) (1)
- Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply (2015) (1)
- Clinical Outcomes of Weekly Prophylaxis with rFVIIIFc: Longitudinal Analysis of the A-LONG and ASPIRE Study Population (2017) (1)
- Comment on Ferroni et al.: “Impact of chemotherapy on venous thromboembolism. (2014) (1)
- Repeated Testing Unfolds the Challenge of Diagnosing Von Willebrand Disease: Longitudinal Data from the Vienna Bleeding Biobank (2022) (0)
- Thrombophilia (2002) (0)
- Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region (2016) (0)
- [Tumor and thrombosis]. (2012) (0)
- Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness Biomarkers and Venous Thromboembolism (2009) (0)
- Neutrophil-to-Lymphocyte Ratio and the Risk of Venous Thromboembolism and Mortality in Patients with Cancer (2018) (0)
- PS1582 DECREASED PLATELET REACTIVITY IS ASSOCIATED WITH AN INFLAMMATORY STATUS IN PATIENTS WITH CANCER (2019) (0)
- Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI (2009) (0)
- Biomarkers of Haemostasis and Occurrence of Venous Thromboembolism Are Associated with Disease Progression and Poor Prognosis in Patients with Pancreatic Cancer (2020) (0)
- Circulatory microRNAs as potential biomarkers for major adverse cardiac events in patients with atrial fibrillation (2021) (0)
- Factors influencing bleeding severity in adult patients with primary immune thrombocytopenia (2021) (0)
- International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients (2012) (0)
- Oral contraceptives in patients with protein C or protein S deficiency: Risk assessment and impact on screening procedures (1996) (0)
- Highly Procoagulant Extracellular Vesicles in Amniotic Fluid (2016) (0)
- Abstract related to PL-22 Guidelines for antithrombotics in cancer patients (2012) (0)
- Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy (2016) (0)
- Chronic pulmonary hypertension 47 P327 | BEDSIDE The right to left atrial and ventricular area ratio, left ventricular area,TAPSE and right ventricular global strain can predict three-year survival in patients with pulmonary hypertension (0)
- The Prothrombotic Polymorphism Prothrombin G20210A Is an Ancestral Mutation That Arose in Caucasians Approximately 20,000 Years Ago. (2005) (0)
- Correlation of systemic and local inflammation with survival prognosis in glioma patients. (2019) (0)
- 556PINTEGRIN BETA-3 GENETIC VARIANTS PREDICT THE RISK OF THROMBO-EMBOLIC EVENTS IN PATIENTS WITH COLORECTAL CANCER. (2014) (0)
- [Various forms of hypoventilation syndromes]. (1987) (0)
- Lupus anticoagulant (LAC), anticardiolipin antibodies (ACA) and thrombosis (1990) (0)
- Platelet Function and Activation in Patients with Immune Thrombocytopenia Treated with Eltrombopag: Comparison with Steroid-Treated and Untreated Patients, (2011) (0)
- Dosing of Rviii-Singlechain Based on Clinical Bleeding Phenotypes Results in Low Bleeding Rates and Low Consumption in Patients Treated with Prophylaxis Two or Three Times Weekly (2016) (0)
- Association of telomere length and mitochondrial DNA copy number, two biomarkers of biological aging, with the risk of venous thromboembolism. (2023) (0)
- Monitoring of decoppering therapy in patients with Wilson's disease by serial determination of serum ceruloplasmin (1989) (0)
- OC-11 Plasminogen activator inhibitor 1 enhances venous thrombosis in pancreatic cancer (2021) (0)
- PO-32 Prediction of venous thromboembolism in cancer patients by measuring thrombin generation – Results from the Vienna Cancer and Thrombosis Study (CATS) (2010) (0)
- Long-term Efficacy and Safety of rVIII-SingleChain in Patients with Severe Hemophilia A: Interim Results of an Extension Study (2019) (0)
- Annexin A5 Resistance Is Associated with Thrombotic Risk in Patients with the Lupus Anticoagulant: The Vienna Lupus Anticoagulant and Thrombosis Study (LATS) (2015) (0)
- Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) (0)
- Prevention and Therapy of Pregnancy-Associated Thromboembolic Events (2008) (0)
- Integrin genetic variants and risk of thromboembolic events in patients with colorectal cancer. (2014) (0)
- Association of Elevated Soluble P-Selectin Levels and Fetal Loss in Women with a History of Venous Thromboembolism. (2008) (0)
- Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status (2023) (0)
- PO-36 A high platelet count independently predicts venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) (2007) (0)
- Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm (2021) (0)
- P1663: THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA (2022) (0)
- The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors (2018) (0)
- Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients, (2011) (0)
- Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a (2016) (0)
- [Fibrin synthesis and fibrinolysis: biochemistry, physiology and molecular biology]. (2004) (0)
- Clinical Features of VTE and Risk Factors for Thrombosis in the Patient Group (2001) (0)
- Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia (2019) (0)
- Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillation (2021) (0)
- Correction to: Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding (2019) (0)
- Rviii-Singlechain Pharmacokinetics and Safety in Children Less Than 12 Years of Age (2015) (0)
- The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS (2010) (0)
- women with a history of venous thromboembolism Temporary increase in the risk of recurrence during pregnancy in (2013) (0)
- Contents Vol. 32, 2002 (2002) (0)
- Clinical haemophilia Long-term safety and efficacy of recombinant factor VIII Fc fusion protein ( rFVIIIFc ) in subjects with haemophilia (2016) (0)
- P1665: WHOLE-BLOOD ROTATIONAL THROMBOELASTOMETRY (ROTEM) AS A DIAGNOSTIC TOOL IN PATIENTS WITH BLEEDING OF UNKNOWN CAUSE (BUC) (2022) (0)
- ORAL ANTICOAGULANTS AND FETAL LOSS. AUTHORS' REPLY (1996) (0)
- Thrombomodulin in patients with mild to moderate bleeding tendency (2021) (0)
- High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients. (2009) (0)
- P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer (2019) (0)
- Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia. (2023) (0)
- Research and Practice in Thrombosis and Haemostasis – a new ISTH publishing platform for the global thrombosis and hemostasis community (2017) (0)
- TEMPORARY REMOVAL: PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer. (2022) (0)
- The risk of recurrent venous thromboembolic disease-implications for treatment (2000) (0)
- Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis (2020) (0)
- Drought and malaria retreat in the Sahel , West Africa (2002) (0)
- Growth differentiation factor-15 (GDF-15) predicts major bleeding, major adverse cardiac events, and mortality in patients with end-stage kidney disease on hemodialysis: findings from the VIVALDI study. (2022) (0)
- Delayed Plasma Clot Lysis in Adult Patients with Primary Immune Thrombocytopenia (ITP) (2021) (0)
- Age-related changes of neutrophil characteristics, potential of activation, DNA release and NET formation (2020) (0)
- Venous Thromboembolism — A Metabolic Disease? (2008) (0)
- Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting (2022) (0)
- 1824P Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors (2020) (0)
- Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion (2015) (0)
- Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a (2019) (0)
- Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study (2022) (0)
- Long-term Safety and Efficacy of rIX-FP in Patients with Hemophilia B: Intermediate Results from a Phase IIIb Extension Study (2019) (0)
- [The Club of Female Professors of the Medical University Vienna]. (2009) (0)
- Extracellular vesicle-associated tissue factor activity is increased in prostate cancer patients with disseminated intravascular coagulation and induced by cellular interactions in vitro (2018) (0)
- CLINICAL SIGNIFICANCE OF MICROPARTICLES (2007) (0)
- Poster Presentations (2016) (0)
- Plasma levels of soluble P-selectin predict survival in CTEPH (2013) (0)
- Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A (2012) (0)
- THROMBOSIS AND HEMOSTASIS Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism (2017) (0)
- Oral anticoagulants and fetal loss (1996) (0)
- Expert Report on Immune Thrombocytopenia - Current Diagnostics and Treatment Recommendations from an Expert Group from Austria, Germany, and Switzerland. (2023) (0)
- Abstracts of the 8th European Symposium on Platelet and Granulocyte Immunobiology, Seehotel Rust, Rust, Austria, May 13–16, 2004 (2004) (0)
- AB0590 A validation study of the pregnancy morbidity questionnaire(PMQ) in women with antiphospholipid antibodies and pregnancy morbidity (2018) (0)
- Dosing regimens before and following long-term treatment with recombinant factor VIII Fc fusion protein (rFVIIIFc) in adults and adolescents with severe hemophilia A (2016) (0)
- Alterations of blood coagulation in controlled human malaria infection (2016) (0)
- P1669: AUTOANTIBODY-MEDIATED PLATELET DESIALYLATION IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (2022) (0)
- Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer (2022) (0)
- Platelets in Deep Venous Thrombosis and Pulmonary Embolism (2017) (0)
- Post-surgical hemorrhagic infarction of the adrenal gland as the first clinical manifestation of antiphospholipid syndrome after 43 years of antibody-positivity (2013) (0)
- Differences in the platelet proteome between patients with cancer at high risk of venous thromboembolism and healthy controls (2018) (0)
- Intraperitoneal activation of the coagulation system via tissue factor-exposing extracellular vesicles and enhanced fibrinolysis in patients with advanced chronic liver disease and ascites (2019) (0)
- PO-92 Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study (2021) (0)
- S1644 ASSOCIATION OF SYSTEMIC CYTOKINE LEVELS WITH RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH GLIOMA (2019) (0)
- Title Page / Table of Contents / Preface (2003) (0)
- 47th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung) 15-18 February 2003, Innsbruck, Austria S1 (2003) (0)
- SAT-077-Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease (2019) (0)
- Hemophilia 2000 — the Annual Survey of the Austrian Hemophilia Centers (2002) (0)
- Accelerated endoplasmic reticulum and coagulation factor processing in platelets are linked with the hypercoagulable state of patients with lung cancer (2021) (0)
- Increased soluble thrombomodulin influences fibrin clot formation in patients with mild to moderate bleeding tendency (2021) (0)
- Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer (2021) (0)
- P-selectin ready for the News at Six (2009) (0)
- Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation (2023) (0)
- Table of Contents (2016) (0)
- D-dimer levels and prediction of overall survival in cancer patients. (2010) (0)
- P-052: Mild-to-moderate bleeding tendency of unknown cause is common in women and might be caused by increased fibrinolysis (2017) (0)
- Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer (2022) (0)
- Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant (2021) (0)
- Anticoagulation in non-malignant portal vein thrombosis is associated with improved hepatic function (2017) (0)
- SP538SOLUBLE P-SELECTIN PREDICTS CARDIOVASCULAR EVENTS IN END STAGE RENAL DISEASE (2015) (0)
- Long-term efficacy and safety of rIX-FP prophylaxis in adult patients with haemophilia B on a 21-day dosing regimen (2021) (0)
- The influence of cancer on platelet behaviour Thrombocytosis in cancer (2017) (0)
- Growth Differentiation Factor-15: a Novel Biomarker for Predicting Risk of Venous Thromboembolism and Bleeding in Patients with Cancer. (2022) (0)
- Epidemiology, risk profile, management, and outcome in geriatric patients with atrial fibrillation in two long-term care hospitals (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ingrid Pabinger?
Ingrid Pabinger is affiliated with the following schools:
